Feb 12 (Reuters) - Pfizer Inc:
* U.S., EU AND JAPAN HEALTH AUTHORITIES ACCEPT REGULATORY SUBMISSIONS FOR REVIEW OF PFIZER’S THIRD-GENERATION ALK INHIBITOR LORLATINIB
* PFIZER INC - U.S. NEW DRUG APPLICATION FOR LORLATINIB GRANTED FDA PRIORITY REVIEW Source text for Eikon: Further company coverage: